InMed Pharmaceuticals Inc
INM2.341USD
-0.049-2.05%
Market hours （ET）Quotes delayed by 15 min
2.83MMarket Cap
LossP/E TTM
More Details of InMed Pharmaceuticals Inc Company
InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
Company Info
Ticker SymbolINM
Company nameInMed Pharmaceuticals Inc
IPO dateJun 21, 2001
CEOMr. Eric A. Adams
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJun 21
Address1445-885 West Georgia St.
CityVANCOUVER
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeV6C 3E8
Phone16046697207
Websitehttps://www.inmedpharma.com/
Ticker SymbolINM
IPO dateJun 21, 2001
CEOMr. Eric A. Adams
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
-18.19%
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
-99.90%
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
-99.96%
Mr. Bryan T. Baldasare
Mr. Bryan T. Baldasare
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-100.00%
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. N. Netta (Neeta) Jagpal, CPA
Ms. N. Netta (Neeta) Jagpal, CPA
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
-18.19%
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
-99.90%
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
-99.96%
Mr. Bryan T. Baldasare
Mr. Bryan T. Baldasare
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-100.00%
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Jul 11
Updated: Fri, Jul 11
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Yorkville Advisors Global, LP.
6.66%
Sabby Management, LLC
2.99%
UBS Financial Services, Inc.
0.51%
Adams (Eric Ashley)
0.18%
Hull (Andrew Harold)
0.16%
Other
89.50%
Shareholders
Shareholders
Proportion
Yorkville Advisors Global, LP.
6.66%
Sabby Management, LLC
2.99%
UBS Financial Services, Inc.
0.51%
Adams (Eric Ashley)
0.18%
Hull (Andrew Harold)
0.16%
Other
89.50%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
9.65%
Individual Investor
0.98%
Investment Advisor
0.51%
Research Firm
0.03%
Other
88.84%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
37
127.03K
10.52%
+19.01K
2025Q1
34
127.03K
10.75%
+32.44K
2024Q4
33
169.52K
14.04%
+76.54K
2024Q3
35
65.17K
63.92%
+11.73K
2024Q2
34
30.10K
7.60%
-6.51K
2024Q1
33
42.40K
13.49%
-1.13K
2023Q4
31
40.41K
15.37%
-91.29K
2023Q3
32
1.59K
1.33%
-12.58K
2023Q2
37
1.04K
0.99%
-13.60K
2023Q1
44
5.33K
3.61%
-4.80K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Yorkville Advisors Global, LP.
80.37K
6.66%
+80.37K
--
Dec 13, 2024
Sabby Management, LLC
36.13K
2.99%
+20.77K
+135.22%
Dec 31, 2024
UBS Financial Services, Inc.
6.11K
0.51%
-4.30K
-41.33%
Mar 31, 2025
Adams (Eric Ashley)
7.89K
0.65%
+5.70K
+259.26%
May 11, 2025
Hull (Andrew Harold)
2.34K
0.19%
+425.00
+22.23%
May 11, 2025
SBI Securities Co., Ltd.
300.00
0.02%
+300.00
--
Mar 31, 2025
Banque Cantonale Vaudoise
6.00
0%
--
--
Mar 31, 2025
Hsu (Eric Chih-Hsien)
1.95K
0.16%
+1.95K
+97300.00%
May 11, 2025
AllSquare Wealth Management LLC
1.00
0%
--
--
Mar 31, 2025
Desjardins Securities Inc.
1.00
0%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
AdvisorShares Pure Cannabis ETF
0%
AdvisorShares Pure Cannabis ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 12, 2024
Merger
20<1
Nov 12, 2024
Merger
20<1
Nov 12, 2024
Merger
20<1
Nov 12, 2024
Merger
20<1
Aug 26, 2022
Merger
25<1
Aug 26, 2022
Merger
25<1
Date
Type
Ratio
Nov 12, 2024
Merger
20<1
Nov 12, 2024
Merger
20<1
Nov 12, 2024
Merger
20<1
Nov 12, 2024
Merger
20<1
Aug 26, 2022
Merger
25<1
Aug 26, 2022
Merger
25<1
Aug 26, 2022
Merger
25<1
Aug 26, 2022
Merger
25<1
